Synapse - Biostatistics Service

Results (71)

Body mass index and somatic variants in biliary tract cancers

Meeting Abstract

Al Mahmasani, L.; Chou, J.; Capanu, M.; Srivastava, A.; Sigel, C.; Alsuwailem, R.; Berger, M.; Khalil, D.; Harding, J. J.; O'Reilly, E. M.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases

Journal Article

Wilcox, J. A.; Jeng, M. Y.; Tischfield, S.; Sui, J. S. Y.; Nemirovsky, D.; Heller, G.; Choudhury, N. J.; Ross, J. S.; Rudin, C. M.; Riely, G. J.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: A pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials

Journal Article

Williams, H.; Fokas, E.; Diefenhardt, M.; Lee, C.; Verheij, F. S.; Omer, D. M.; Lin, S. T.; Dunne, R. F.; Marcet, J.; Cataldo, P.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)

Meeting Abstract

Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

Meeting Abstract

Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)

Meeting Abstract

Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma

Meeting Abstract

Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients

Meeting Abstract

Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum

Meeting Abstract

Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save